AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:50 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

01 May 2023 07:00:31 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

21 Apr 2023 07:00:34 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

14 Apr 2023 07:00:49 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

13 Apr 2023 07:00:34 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

22 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

31 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

07 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

28 Nov 2022 06:35:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

23 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

09 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022

21 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

20 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022

10 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

03 Oct 2022 06:30:00 By Nasdaq GlobeNewswire